Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study maps disease progression in Parkinson's and MSA

NCT ID NCT05699460

Knowledge-focused Sponsor: AskBio Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study follows 150 people with early Parkinson's disease or Multiple System Atrophy (MSA) for up to 18 months. Researchers will measure changes in motor symptoms, quality of life, and biomarkers to better understand how these diseases progress. The goal is to gather information that could help design future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help researchers better understand how Parkinson's disease and Multiple System Atrophy progress, potentially guiding future treatments.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new therapy, and results may not lead directly to new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

73 people

The number who actually took part.

Started

Sep 2022

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will have a diagnosis of early Parkinson's disease OR possible or probably MSA-P

Ages

35 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Idiopathic PD * Diagnosis of MSA-P * One to six years from clinical diagnosis of PD * Less than 4 years from clinical diagnosis of MSA with expected survival \>3 years * Stable medication regimen * Ability to walk with or without an assistive device Exclusion Criteria: * Movement disorder due to known cerebrovascular disease, brain tumor, trauma, exposure to parkinsonian-linked toxicants or other neurological diseases * Presence of dementia, psychosis, substance abuse or poorly controlled depression * Prior brain surgery (i.e. deep brain stimulation) or other brain imaging abnormalities * History of cancer or poorly controlled medical conditions * Receiving an investigational drug NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple system atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple system atrophy multiple system atrophy, parkinsonian type Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy Multiple system atrophy, Parkinson variant Parkinson's disease

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mazowiecki Szpital Bródnowski w Warszawie, Oddział Neurologii

    Warsaw, Poland

  • OHSU Parkinson Center & Movement Disorders Program

    Portland, Oregon, 97239, United States

  • Ohio Health Research Institute

    Columbus, Ohio, 43214, United States

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486, United States

  • Quest Research Institute

    Farmington Hills, Michigan, 48334, United States

  • Samodzielny Publiczny Szpital Kliniczny im. prof. Witolda Orłowskiego, Oddział Neurologii i Epileptologii

    Warsaw, Poland

  • Specjalistyczna Praktyka Lekarska, Prof. Grzegorz Opala

    Katowice, Poland

  • University of California Irvine

    Irvine, California, 92697, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Zespol Poradni Specjalistycznych - Botaniczna 3 Poradnia Neurologiczna Szpital Uniwersytecki w Krakowie

    Krakow, Lesser Poland Voivodeship, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.